Inventor · disambiguated record
Mark Paris
Also filed as: PARIS MARK · PARIS MARK J
12 granted patents·7 pending applications·40 citations·filing 2004–2024
88Inventor score
Top patents by PatentIndex Score
19 records- 0192US12006365B2Human anti-semaphorin 4D antibodyVACCINEX INC·Filed 2022·Granted Jun 11, 2024·1 cites·27 claims
- 0289US9708601B2Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virusVACCINEX INC·Filed 2013·Granted Jul 18, 2017·7 cites·4 claims
- 0388US9701958B2Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunitsVACCINEX INC·Filed 2015·Granted Jul 11, 2017·4 cites·13 claims
- 0487US10577427B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2017·Granted Mar 3, 2020·3 cites·12 claims
- 0585US11427634B2Human anti-semaphorin 4D antibodyVACCINEX INC·Filed 2018·Granted Aug 30, 2022·4 cites·50 claims
- 0685US10550199B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2019·Granted Feb 4, 2020·2 cites·24 claims
- 0783US8834883B2Anti-VEGF antibodies and uses thereofCROY LESLIE A·Filed 2011·Granted Sep 16, 2014·9 cites·34 claims
- 0881US9963504B2Anti-CXCL13 antibodies and methods of using the sameKLIMATCHEVA EKATERINA·Filed 2011·Granted May 8, 2018·10 cites·14 claims
- 0980US2024309091A1Human anti-semaphorin 4d antibodyVACCINEX INC·Filed 2024·Application pending·0 cites
- 1069US10870707B2Integral membrane protein display on poxvirus extracellular enveloped virionsVACCINEX INC·Filed 2019·Granted Dec 22, 2020·0 cites·15 claims
- 1168US11981730B2Anti-CXCL13 antibodies and methods of using the sameVACCINEX INC·Filed 2020·Granted May 14, 2024·0 cites·12 claims
- 1262US10829550B2Polynucleotides encoding anti-CXCL13 antibodiesVACCINEX INC·Filed 2018·Granted Nov 10, 2020·0 cites·14 claims
- 1359US10662422B2Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunitVACCINEX INC·Filed 2017·Granted May 26, 2020·0 cites·4 claims
- 1459US2005158323A1Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cellsVACCINEX INC·Filed 2004·Application pending·0 cites
- 1555US2004210037A1Targeted MHC class I alpha3 vaccine delivery systemsVACCINEX INC·Filed 2004·Application pending·0 cites
- 1654US2008305111A1Anti-C35 antibodies for treating cancerVACCINEX INC·Filed 2007·Application pending·0 cites
- 1753US2005266425A1Methods for producing and identifying multispecific antibodiesVACCINEX INC·Filed 2004·Application pending·0 cites
- 1853US2009081210A1Methods of Killing Tumor Cells by Targeting Internal Antigens Exposed on Apoptotic Tumor CellsVACCINEX INC·Filed 2008·Application pending·0 cites
- 1942US2016002325A1Anti-cxcl13 antibodies and associated epitope sequencesVACCINEX INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Paris files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →